Estriol is named as an intervention in 2 current clinical trials in our Turkey and Brazil registers. None are recruiting at the moment. The most common phase is Phase 3. The sponsor with the most trials is Hatice Tukenmez Kurnaz (1). The most-studied condition is Pelvic Organ Prolapse.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Effect of Local Estriol Treatment Before Vaginal Repair Surgery
NCT06391372 · ClinicalTrials.gov ↗ · Pelvic Organ Prolapse, Pelvic Floor Disorders, Menopause
|
Phase 3 | Active, closed | Hatice Tukenmez Kurnaz | Turkey |
|
LASER and Radiofrequency and Genitourinary Syndrome of Menopause
NCT04045379 · ClinicalTrials.gov ↗ · Postmenopausal Atrophic Vaginitis, Postmenopausal Symptoms, Genitourinary Symptoms
|
Not applicable | Active, closed | Federal University of São Paulo | Brazil |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
4 single-substance products containing Estriol on the HPRA medicines list.
No entry for Estriol in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Hatice Tukenmez Kurnaz | 1 |
| Federal University of São Paulo | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Turkey | 1 | 0 |
| Clinical trials in Brazil | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Turkey and Brazil registers name Estriol as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Hatice Tukenmez Kurnaz (1) and Federal University of São Paulo (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 4 single-substance products containing Estriol, for example Ovestin 1 mg per gram Vaginal Cream (Aspen Pharma Trading Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Estriol has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Estriol works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Estriol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Estriol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.